

**Company Focus** 

11 October 2007 | 8 pages

# Spice Communications (SPCM.BO)

## **Buy: 3Q07 – Margin Improvement, but Net Below Expectations**

- EBITDA margin a positive surprise 3Q07 revenue at Rs2,522m was in line with EBITDA at Rs614m, providing the positive surprise led mainly by stable to declining SG&A expenses. The EBITDA margin expanded by a robust 350bp qoq. This was however offset by lower-than-expected other income, resulting in recurring net profit at only Rs31m. Exceptionals of Rs11.6m resulted in a reported loss at the net level.
- Modifying estimates to align quarterlies We upgrade CY07 EBITDA by 3% but adjust CY08-09 estimates downwards by 4-5% to factor in more conservative sub adds albeit at higher EBITDA margins. Other assumptions relating to ARPU, MoU and capex payback period remain broadly similar. Higher tenancy on third-party towers (on which Spice is anchor tenant now) will also aid margin improvement.
- Margin improvement, a trend to watch in Sep quarter— Expected margin improvements in the quarter under review and beyond was one of the key reasons for our recent upgrade of the frontline stocks. Spice's results could therefore be an indication of things to come.
- Maintain Buy/Medium Risk Access to the 900 MHz spectrum and small footprint make Spice an M&A target, in our view. Though new spectrum recommendations may dilute its attractiveness, it opens up the organic route for growth on the flip side, albeit constrained by balance sheet size. Our target price of Rs70 (incl. 15% M&A premium to DCF) remains unchanged.

#### Figure 1. Statistical abstract

	Revenue (Rs m)	EBITDA (Rs m)	Net Profit (Rs m)	FD EPS (Rs)	P/E (x)	EV/EBITDA (x)
Jun 04-May 05	6,066	1,665	74	0.1	NA	25.1
Jun 05-Dec 06	10,466	2,353	(1,105)	(2.0)	NA	30.5
CY07E	9,738	2,307	46	0.1	NA	20.7
CY08E	13,271	3,536	718	1.0	57.7	14.1
CY09E	16,315	4,826	1,571	2.3	26.4	10.4


Source: Company and Citi Investment Research estimates

See Appendix A-1 for Analyst Certification and important disclosures.

Estimate change 🗹

Buy/Medium Risk	1 M
Price (11 Oct 07)	Rs53.50
Target price	Rs70.00
Expected share price return	30.8%
Expected dividend yield	0.0%
Expected total return	30.8%
Market Cap	Rs36,911M
	US\$943M

# Price Performance (RIC: SPCM.BO, BB: SPCM IN)



#### Rahul Singh<sup>1</sup>

+91-22-6631-9863 rahul.r.singh@citi.com

Gaurav Malhotra<sup>1</sup>

gaurav.a.malhotra@citi.com

Anand Ramachandran, CFA<sup>2</sup>

+852-2501-2448 anand.ramachandran@citi.com

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. <sup>1</sup>Citigroup Global Markets India Private Limited; <sup>2</sup>Citigroup Global Markets Asia

Valuation Ratios         nm         nm         nm         nm         nm         nm         state         Pf2 adjusted (x)         Pf2 adjust	Fiscal year end 31-Dec	Jul04-Jun05	Jul05-Dec06	2007E	2008E	2009E
EV/EBT/DA adjusted (x)         28.2         30.5         19.9         12.8         9.6           P/BV (x)         nm         nm         7.6         6.6         5.2           Dividend yield (%)         0.0         0.0         0.0         0.0         0.0           PS adjusted         0.13         -2.00         0.07         1.04         2.28           EYS reported         0.13         -2.00         0.00         0.00         0.00           PS         0.00         0.00         0.00         0.00         0.00           PS         0.00         0.00         0.00         0.00         0.00           Operating expenses         -5.640         -10.281         -9.009         -11.908         -14.001           EBIT         426         185         729         1.364         2.313           Non-operating expense         -3.50         -1.231         -6.09         0         0         0           Pre-tax profit         76         -1.087         51         722         1.364         7.137           Cax         -2         -1.8         5         -5         -5         5         5         5         5         5         5 <td< td=""><td>Valuation Ratios</td><td></td><td></td><td></td><td></td><td></td></td<>	Valuation Ratios					
EV/EBT/DA adjusted (x)         28.2         30.5         19.9         12.8         9.6           P/BV (x)         nm         nm         7.6         6.6         5.2           Dividend yield (%)         0.0         0.0         0.0         0.0         0.0           PS adjusted         0.13         -2.00         0.07         1.04         2.28           EYS reported         0.13         -2.00         0.00         1.00         0.00           PS         0.00         0.00         0.00         0.00         0.00           PS         0.00         0.00         0.00         0.00         0.00           Operating expenses         -5.640         -10.281         -9.009         -11.908         -14.001           EBIT         426         185         729         1.364         2.313           Non-operating expense         -350         -1.231         -6.09         -14.00         0         0           Pre-tax profit         76         -1.087         51         722         1.355         -5         -5         5         5         5         5         5         5         5         5         5         5         5         5         5 <td>P/E adjusted (x)</td> <td>nm</td> <td>nm</td> <td>nm</td> <td>53.3</td> <td>24.3</td>	P/E adjusted (x)	nm	nm	nm	53.3	24.3
Dividend yield (%)         0.0         0.0         0.0         0.0         0.0           Per Sarae Data (Rs)         EPS adjusted         0.13         -2.00         0.07         1.04         2.28           EPS reported         0.13         -2.00         0.07         1.04         2.28           BVPS         -0.40         -2.40         7.31         8.35         10.63           DPS         0.00         0.00         0.00         0.00         0.00           Porfit & Loss (RsM)         Net sales         6.066         10.466         9.738         13.271         16.315           Deprating expenses         -5.640         -10.281         -9.009         -11.908         -14.00           Non-operating/exceptionals         0         -41         0         0         0         0           Pre-tax profit         76         -1.231         -679         -641         -738         1.571           Adjusted eminings         74         -1.105         46         718         1.571           Adjusted eminings         74         -1.105         46         718         1.571           Adjusted eminings         74         -1.054         713         2.53         2.307		28.2	30.5	19.9	12.8	9.6
Per Share Data (Rs)           EPS adjusted         0.13         -2.00         0.07         1.04         2.28           BYRS         -0.40         -2.40         7.31         8.35         10.63           DPS         0.00         0.00         0.00         0.00         0.00           Profit & Loss (RsM)         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         0.00						
EPS adjusted         0.13         -2.00         0.07         1.04         2.28           EPS reported         0.13         -2.00         0.07         1.04         2.28           EPS reported         0.13         -2.00         0.07         1.04         2.28           DPS         0.00         0.00         0.00         0.00         0.00         0.00           Profit & Loss (RsM)         Net sales         6,066         10.466         9,738         13,271         16,315           Operating expenses         -5,640         -10.281         -9,009         -11,908         -14,001           EBIT         426         185         729         1,364         2,313           Non-operating/exceptionals         0         -41         0         0         0           Pre-tax profit         76         -1.087         51         722         1,376           Tax         -2         1.8         -5         -5         -5         5           Adjusted tining/scorpt net income         74         -1,105         46         718         1,571           Adjusted ting them         1,243         -3,16         33.3         36.5         22.9         2,506         4,533		0.0	0.0	0.0	0.0	0.0
EFS reported         0.13         -2.00         0.07         1.04         2.28           BVPS         -0.40         -2.40         7.31         8.35         10.63           DPS         0.00         0.00         0.00         0.00         0.00           Porfit & Loss (RsM)         Net sales         6.066         10.466         9.738         13.271         16.315           Operating expenses         -5.640         -10.281         -9.009         -11.908         -14.00           Non-operating/exceptionals         0         -41         0         0         0         0           Non-operating/exceptionals         0         -1.087         51         722         1.576           Tax         -2         -1.8         -5         -5         -5           Extraord/Min.Int./Pref.div.         0         0         0         0         0         0           Adjusted EBTDA         1.665         2.353         2.307         3.536         4.825           BBT adjusted         58.2         -71.0         491.3         87.0         69.65           EBIT Adjusted EDTDA         1.655         2.307         3.536         4.825           Derek asprofitow         1.						
BYPS         -0.40         -2.40         7.31         8.35         10.63           DPS         0.00         0.00         0.00         0.00         0.00           Profit & Loss (RsM)         Net sales         6.066         10.466         9.738         13.271         16.315           Operating expenses         -5.640         -10.281         -9.009         -11.908         -14.011           EBIT         426         185         729         1,384         2,313           Non -operating/exceptionals         0         -41         0         0         0           Ter-tax profit         76         -1.087         51         722         1,356           Tax         -2         -18         -5         -5         5           Extraord/Min.Int/Pref.div.         0<						
DPS         0.00         0.00         0.00         0.00         0.00           Profit & Loss (RsM)         .	•					
Profit & Loss (RsM)           Net sales         6.066         10.466         9.738         13,271         16,315           Operating expenses         -5,640         -10,281         -9,009         -11,308         -14,001           EBIT         426         185         729         1,364         2,313           Non -operating/exceptionals         0         -41         0         0         0           Pre-tax profit         76         -1,087         51         722         1,376           Tax         -2         -18         -5         -5         -5           Extraord/Min.Int/Pref.div.         0						
Net sales         6,066         10,466         9,738         13,271         16,315           Operating expenses         -5,640         -10,281         -9,009         -11,908         -14,001           ENT         426         185         729         1,364         2,331           Non-operating/exceptionals         0         -41         0         0         0           Pre-tax profit         76         -1,087         51         722         1,376           Tax         -2         -18         -5         -5         -5           Extraord/Min.Int/Pref.div.         0         0         0         0         0           Reported net income         74         -1,105         46         718         1,571           Adjusted EBITDA         1,665         2,333         2,307         3,536         4,826           Growth Rates (%)         Sales         13.1         15.0         39.6         36.3         22.9           EBITDA dijusted         10.7         -5.8         41         53.3         36.5         25.93         2,173         2,513           Net working capital         388         -316         331         301         7           Ibirodis						
Operating expenses         -5.640         -10.281         -9.009         -11.908         -14.001           EBT         426         185         729         1.364         2.313           Non-operating/exceptionals         0         -41         0         0         0           Pre-tax profit         76         -1.037         51         722         1.576           Tax         -2         -18         -5         -5         -5           Extraord./Min.Int./Pref.div.         0         0         0         0         0           Adjusted earnings         74         -1.105         46         718         1.571           Adjusted earnings         74         -1.105         46         718         1.571           Adjusted EBITDA         1.665         2.353         2.307         3.536         4.826           BIT adjusted         58.2         -71.0         491.3         87.0         696.           EBIT Adjusted         10.7         -5.8         47.1         53.3         36.5           EDITA adjusted         1.239         2.168         1.577         2.173         2.513           Operating cash flow         1.448         2.389         -5.066		6 066	10 466	9 738	13 271	16 315
EBIT         426         185         729         1,364         2,313           Net interest expense         -350         -1,231         -679         -641         -738           Non-operating/exceptionals         0         -41         0         0         0         0           Tax         -2         -18         -5         -5         -5         -5           Extraort //in/in/in//Pref.div.         0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Non-operating/exceptionals         0         -41         0         0         0           Pre-tax profit         76         -1,087         51         722         1,576           Tax         -2         -18         -5         -5         -5           Extraord./Min.Int./Pref.div.         0         0         0         0         0           Repreted net income         74         -1,105         46         718         1,571           Adjusted EBITDA         1,665         2,353         2,307         3,536         4,826           Growth Rates (%)           3         4,826         13.1         15.0         39.6         36.3         22.9           BBIT adjusted         58.2         -71.0         491.3         87.0         69.6         18.9           Cash Flow (RSM)          -132.8         -1,097.4         -105.2         1,468.6         118.9           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Cash Flow (RSM)          0         7         0         0         0           Capital expenditure         -1,243         -3,416         -3,899         -5,0						
Pre-tax profit         76         -1,087         51         722         1,576           Tax         -2         -18         -5         -5         -5           Extraord/Min.Int/Pref.div.         0         0         0         0         0           Reported net income         74         -1,105         46         718         1,571           Adjusted earnings         74         -1,105         46         718         1,571           Adjusted EBITDA         1,665         2,353         2,307         3,536         4,826           Growth Rates (%)           39.6         36.3         22.9           Sales         13.1         15.0         39.6         36.3         22.9           EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           ESS adjusted         -132.8         -1,097.4         -105.2         1,488.6         118.9           Cash Flow (RsM)           1,458         2,133         301         7           Operating cash flow         -1,468         2,108         2,490         3,786         4,812           Acquisitions/disposals         0         0         0			,			
Tax         -2         -18         -5         -5         -5           Extraord/Min.Int/Pref.div.         0         0         0         0         0         0           Reported net income         74         -1,105         46         718         1,571           Adjusted earnings         74         -1,105         46         718         1,571           Adjusted EBITDA         1,665         2,353         2,307         3,536         4,826           Growth Rates (%)         Sales         13.1         15.0         39.6         36.3         22.9           EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           EBIT adjusted         10.7         -5.8         47.1         53.3         36.5           EPS adjusted         -132.8         -1,097.4         -105.2         1,468.6         118.9           Operating cash flow         1,468         2,108         2,490         3,786         4,812           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow						
Extraord //Min.Int./Pref.div.         0         0         0         0         0         0           Reported net income         74         -1,105         46         718         1,571           Adjusted BITDA         1,665         2,353         2,307         3,536         4,826           Growth Rates (%)         Sales         13.1         15.0         39.6         36.3         22.9           EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           EBITDA adjusted         10.7         -5.8         47.1         53.3         36.5           EPS adjusted         -132.8         -1,097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)         0         0         0         0         0         0           Depreciation/amortization         1.239         2,168         1,577         2,173         2,513           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,5						
Reported net income         74         -1,105         46         718         1,571           Adjusted earnings         74         -1,105         46         718         1,571           Adjusted EBITDA         1,655         2,353         2,307         3,536         4,826           Growth Rates (%)           3         536         2.29           Sales         13.1         15.0         39.6         36.3         22.9           EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           EPS adjusted         -132.8         -1097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)            3         36.5         118.9           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,243         -3,416         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Capital expenditure <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
Adjusted earnings       74       -1,105       46       718       1,571         Adjusted EBITDA       1,665       2,353       2,307       3,536       4,826         Growth Rates (%)       -			-			-
Growth Rates (%)           Sales         13.1         15.0         39.6         36.3         22.9           EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           EBITDA adjusted         10.7         -5.8         47.1         53.3         36.5           EPS adjusted         -132.8         -1.097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)           0perating cash flow         1,468         2,108         2,490         3,786         4,812           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0           Dividends paid         0         7         0         0         0           Dividends paid         0         0         0         0         0         0           Dividends paid         0         0         0         0         <	-	74		46		
Sales         13.1         15.0         39.6         36.3         22.9           EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           EBTDA adjusted         10.7         -5.8         47.1         53.3         36.5           EPS adjusted         -132.8         -1,097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)         Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Borrowings         56         1,105         -4,200         1,000         1,000 <td>Adjusted EBITDA</td> <td>1,665</td> <td>2,353</td> <td>2,307</td> <td>3,536</td> <td>4,826</td>	Adjusted EBITDA	1,665	2,353	2,307	3,536	4,826
EBIT adjusted         58.2         -71.0         491.3         87.0         69.6           EBITDA adjusted         10.7         -5.8         47.1         53.3         36.5           EPS adjusted         -132.8         -1,097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)         Operating cash flow         1,468         2,108         2,490         3,786         4,812           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Borrowings         56         1,105         -4,200         1,000	Growth Rates (%)					
EBITDA adjusted         10.7         -5.8         47.1         53.3         36.5           EPS adjusted         -132.8         -1,097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)         Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0           Dividends paid         0         0         0         0         0           Dividends paid         0         0         0         0         0           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Cash &						
EPS adjusted         -132.8         -1,097.4         -105.2         1,468.6         118.9           Cash Flow (RsM)         Operating cash flow         1,468         2,108         2,490         3,786         4,812           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0         0           Financing cash flow         -248         411         1,444         359         262           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Cash & cash equivalent         2,099         1,273         1,450         575						
Cash Flow (RsM)         June 1         June 1 <thjune 1<="" th=""> <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td></th<></thjune>						
Operating cash flow         1,468         2,108         2,490         3,786         4,812           Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0           Financing cash flow         -248         411         1,444         359         262           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Accounts receivable         598         545         636         764         826           Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total liabiliti		-152.0	-1,037.4	-105.2	1,400.0	110.5
Depreciation/amortization         1,239         2,168         1,577         2,173         2,513           Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Cash & Cash equivalent         2,099         1,273         1,450         575         1,128           Accounts receivable         598         545         636         764         826           Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total assets         9,001         10,377         12,698         15,592         17,617           Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts		1 /68	2 108	2 /00	3 786	4 812
Net working capital         358         -316         331         301         7           Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0           Financing cash flow         -248         411         1,444         359         262           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Accounts receivable         598         545         636         764         826           Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts payable         1,925         2,625         0         0         0           Total liabilities <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
Investing cash flow         -1,195         -3,345         -3,899         -5,066         -4,538           Capital expenditure         -1,243         -3,416         -3,899         -5,066         -4,538           Acquisitions/disposals         0         7         0         0         0           Financing cash flow         -248         411         1,444         359         262           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Change in cash         26         -826         34         -921         536           Balance Sheet (RsM)         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         0         1,00         1,00         1,20         12,458         13,3						
Acquisitions/disposals         0         7         0         0         0           Financing cash flow         -248         411         1,444         359         262           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Change in cash         26         -826         34         -921         536           Balance Sheet (RsM)         Total assets         12,468         13,380         16,073         18,421         21,180           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Accounts receivable         598         545         636         764         826           Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts payable         1,925         2,625         0         0         0           Total liabilities         -219         -1,324         5,044         5,762         7,332           Shareholders'						-4,538
Financing cash flow         -248         411         1,444         359         262           Borrowings         56         1,105         -4,200         1,000         1,000           Dividends paid         0         0         0         0         0         0           Change in cash         26         -826         34         -921         536           Balance Sheet (RsM)         Total assets         12,468         13,380         16,073         18,421         21,180           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Accounts receivable         598         545         636         764         826           Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts payable         1,925         2,625         0         0         0           Total liabilities         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         27.4         22.5         23.7         26.6	• •					-4,538
Borrowings561,105-4,2001,0001,000Dividends paid00000Change in cash26-82634-921536Balance Sheet (RsM)70112,46813,38016,07318,42121,180Cash & cash equivalent2,0991,2731,4505751,128Accounts receivable598545636764826Net fixed assets9,00110,37712,69815,59217,617Total liabilities12,46813,38011,02912,65913,848Accounts payable1,9252,625000Total Debt10,76212,0797,8798,8799,879Shareholders' funds-219-1,3245,0445,7627,332Profitability/Solvency Ratios (%)27.422.523.726.629.6EBITDA margin adjusted27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6						
Dividends paid         0         0         0         0         0         0         0           Change in cash         26         -826         34         -921         536           Balance Sheet (RsM)         Total assets         12,468         13,380         16,073         18,421         21,180           Cash & cash equivalent         2,099         1,273         1,450         575         1,128           Accounts receivable         598         545         636         764         826           Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts payable         1,925         2,625         0         0         0           Total Debt         10,762         12,079         7,879         8,879         9,879           Shareholders' funds         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         27.4         22.5         23.7         26.6         29.6           ROE adjusted         -28.9         36.1         -4.9	-					
Change in cash26-82634-921536Balance Sheet (RsM)Total assets12,46813,38016,07318,42121,180Cash & cash equivalent2,0991,2731,4505751,128Accounts receivable598545636764826Net fixed assets9,00110,37712,69815,59217,617Total liabilities12,46813,38011,02912,65913,848Accounts payable1,9252,625000Total Debt10,76212,0797,8798,8799,879Shareholders' funds-219-1,3245,0445,7627,332Profitability/Solvency Ratios (%)27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6					,	
Total assets12,46813,38016,07318,42121,180Cash & cash equivalent2,0991,2731,4505751,128Accounts receivable598545636764826Net fixed assets9,00110,37712,69815,59217,617Total liabilities12,46813,38011,02912,65913,848Accounts payable1,9252,625000Total Debt10,76212,0797,8798,8799,879Shareholders' funds-219-1,3245,0445,7627,332Profitability/Solvency Ratios (%)EBITDA margin adjusted27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6						
Total assets12,46813,38016,07318,42121,180Cash & cash equivalent2,0991,2731,4505751,128Accounts receivable598545636764826Net fixed assets9,00110,37712,69815,59217,617Total liabilities12,46813,38011,02912,65913,848Accounts payable1,9252,625000Total Debt10,76212,0797,8798,8799,879Shareholders' funds-219-1,3245,0445,7627,332Profitability/Solvency Ratios (%)EBITDA margin adjusted27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6	Balance Sheet (RsM)					
Cash & cash equivalent2,0991,2731,4505751,128Accounts receivable598545636764826Net fixed assets9,00110,37712,69815,59217,617Total liabilities12,46813,38011,02912,65913,848Accounts payable1,9252,625000Total Debt10,76212,0797,8798,8799,879Shareholders' funds-219-1,3245,0445,7627,332Profitability/Solvency Ratios (%)EBITDA margin adjusted27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6		12,468	13,380	16,073	18,421	21,180
Net fixed assets         9,001         10,377         12,698         15,592         17,617           Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts payable         1,925         2,625         0         0         0           Total Debt         10,762         12,079         7,879         8,879         9,879           Shareholders' funds         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         27.4         22.5         23.7         26.6         29.6           ROE adjusted         -28.9         36.1         -4.9         13.3         24.0           ROIC adjusted         5.0         1.0         4.0         10.9         15.6						
Total liabilities         12,468         13,380         11,029         12,659         13,848           Accounts payable         1,925         2,625         0         0         0           Total Debt         10,762         12,079         7,879         8,879         9,879           Shareholders' funds         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         27.4         22.5         23.7         26.6         29.6           ROE adjusted         -28.9         36.1         -4.9         13.3         24.0           ROIC adjusted         5.0         1.0         4.0         10.9         15.6						
Accounts payable         1,925         2,625         0         0         0           Total Debt         10,762         12,079         7,879         8,879         9,879           Shareholders' funds         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         27.4         22.5         23.7         26.6         29.6           ROE adjusted         -28.9         36.1         -4.9         13.3         24.0           ROIC adjusted         5.0         1.0         4.0         10.9         15.6						
Total Debt         10,762         12,079         7,879         8,879         9,879           Shareholders' funds         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         27.4         22.5         23.7         26.6         29.6           ROE adjusted         -28.9         36.1         -4.9         13.3         24.0           ROIC adjusted         5.0         1.0         4.0         10.9         15.6						
Shareholders' funds         -219         -1,324         5,044         5,762         7,332           Profitability/Solvency Ratios (%)   <						
EBITDA margin adjusted27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6						
EBITDA margin adjusted27.422.523.726.629.6ROE adjusted-28.936.1-4.913.324.0ROIC adjusted5.01.04.010.915.6	Profitability/Solvency Ratios (%)					
ROE adjusted         -28.9         36.1         -4.9         13.3         24.0           ROIC adjusted         5.0         1.0         4.0         10.9         15.6		27.4	22.5	23.7	26.6	29.6
ROIC adjusted         5.0         1.0         4.0         10.9         15.6						
	ROIC adjusted			4.0	10.9	15.6
Net debt to equity na na 127.5 144.1 119.4						
Total debt to capital         102.1         112.3         61.0         60.6         57.4	lotal debt to capital	102.1	112.3	61.0	60.6	57.4

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Figure 2. Quarterly data									
	Jun-06	Sep-06	Dec-06	Mar-07	Jun-07	Sep-07	QoQ (%)	YoY (%)	Comments
Subs (000)	2,055	2,197	2,450	2,729	3,170	3,482	16.2	54.3	104k monthly net adds during the quarter
ARPU (Rs) CIR Estimate	295	286	291	275	262	253	(4.8)	(11.2)	QoQ drop lower than expected
Total revenue	1,764	1,824	2,027	2,137	2,317	2,522	8.4	31.4	
Network Operating costs	579	728	852	673	725	777	7.8	25.4	
Leased charges on passive infra	21	-	-	183	203	216	11.0	NM	Higher tenancy on 3rd party towercos to support margins
Staff +SGA	610	597	618	582	680	672	17.0	11.5	
License fees	154	97	113	188	208	223	10.4	35.1	
Handset costs	-	-	-	34	18	16	(47.0)	NM	
EBITDA	400	402	445	477	483	614	1.2	20.7	Surprised on the positive
PBT	(106)	(254)	(159)	(143)	7	34	NM	NM	
PAT	(109)	(255)	(163)	(147)	4	31	NM	NM	
Source: Citi Investment R	esearch, Co	mpany data							

# **Quarterly performance**

# **Earnings revision**

### What's changed?

We are modifying our estimates to align quarterlies. Our new EBITDA estimates (+3 to -5%) factor in lower monthly net adds (as seen in 2Q07 additions) though accompanied by higher margins (like 2Q) as rising tenancy on the third-party towercos will increasingly support the EBITDA margin.

### Figure 3. Revising estimates

	CY07E	CY08E	CY09E	2 year CAGR (CY07-09)
Subscribers				
Old	4,080	5,825	7,243	
New	3,767	5,280	6,612	32.5%
Change (%)	-7.7%	-9.4%	-8.7%	
YoY change (%)		40.2%	25.2%	
EBITDA				
Old	2,245	3,668	5,051	
New	2,307	3,536	4,826	44.6%
Change (%)	2.7%	-3.6%	-4.5%	
YoY change (%)		53.3%	36.5%	
EBITDA margins				
Old	21.5%	24.8%	27.7%	
New	23.7%	26.6%	29.6%	
Change	2.2%	1.8%	1.9%	
Source: Citi Investment Resea	rch estimates			

### What remains unchanged

#### Figure 4. Key Operating Assumptions Remain Broadly Unchanged

	CY07E	CY08E	CY09E
ARPU			
Old	266	248	232
New	260	244	228
% change	-2.1%	-1.7%	-1.8%
MoU			
Old	386	407	418
New	387	409	419
% change	0.2%	0.4%	0.3%
Rev/min			
Old	0.69	0.61	0.56
New	0.67	0.60	0.54
% change	-2.3%	-2.0%	-2.1%

## **Spice Communications**

### **Company description**

Spice Communications, a pure-play regional wireless provider, is the seventhlargest cellular operator in India and provides services in two circles — Punjab and Karnataka — where it is the incumbent operator. It commenced services in 1996 and listed on the Bombay Stock Exchange (BSE) in July 2007. It is majority owned by the Dilip Modi group and Telekom Malaysia.

### Investment strategy

4

We rate Spice Buy/Medium Risk. Continued robust wireless market expansion and presence in fast growing markets - Punjab (33% penetration) and Karnataka (22%) - offers growth potential as it moves to bolster its inadequate market share in the latter (~9%). This is evident from the recent pick-up in Spice's share of net adds. The company's recent IPO has provided sufficient funding flexibility to pursue its growth plans, at least in these two circles as Spice currently does not face any spectrum constraints. We estimate EBITDA CAGR of 45% over CY06-09E, ahead of all listed peers and more than double that of the broader market. In addition, we believe that Spice's spectrum allocation in the more efficient 900 MHz band and smaller footprint offers good M&A potential in the long run. From an industry perspective, we believe that low revenue yields and moderate EBITDA margins leave little room for disruptive pricing.

### Valuation

Our target price of Rs70 is based on a 15% M&A premium to our core business DCF of Rs60 (as on Dec-08). We prefer DCF as our primary valuation methodology due to the back-ended nature of free cash flows, in the context of coverage ramp-up, especially in Karnataka. Our DCF assumes a WACC of 11% at a target debt to capital of 50.0% and terminal growth rate of 4.0% (similar to Bharti). Our DCF is based on explicit forecasts for CY07-16E with a terminal year EBITDA margin at 35% ( $\sim$ 600bps below Idea) and capex/sales of  $\sim$ 7% (in line with Bharti). The target price implies a CY08E EV/EBITDA of 14.1x (which is 5% premium on pro-rata basis to Bharti's FY09 target ex-towerco), which we believe is supported by significantly higher prospective EBITDA growth rates for Spice. Though Spice rebuffed the moves by Idea pre-IPO, we believe that M&A potential exists in the medium term as access to 900MHz spectrum and its small footprint makes it a good and probably the only M&A candidate, especially with recent relaxation of M&A norms. If the new TRAI spectrum norms are accepted, the opportunity to enter new circles could also justify a premium to the DCF based on its existing two circles.

### Risks


Our quantitative risk-rating system assigns a default Speculative Risk rating to Spice due its trading history of less than 12 months. We see a Medium Risk rating as more appropriate due to the higher visibility of Indian wireless growth, strong parentage (Telekom Malaysia) and lower financial leverage post-IPO. Spice accumulated significant losses in the past resulting in negative net worth prior to the IPO. It previously defaulted on payments to vendors and debenture holders due to lack of adequate funds and has had qualifications from auditors with respect to its ability to continue operations in absence of access to longterm funds. Going forward, operationally, the risks facing Spice are slightly higher than its more established peers given its smaller scale. Lower-thanexpected tenancy in third-party towers and higher capex requirements to increase coverage may depress return parameters. Its equipment sourcing contract with Spice Mobiles Pvt. Ltd, a group company, carries transfer pricing risks as there is lack of clarity on the rationale and cost-plus billing terms. While new circle roll-outs are possible if new spectrum norms are accepted by the DoT (as and when the Defence Department releases spectrum), it will be constrained by management bandwidth and may require a fresh equity infusion. These risk factors could impede the stock from reaching our target price.

# Appendix A-1

## **Analyst Certification**

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research report.

### **IMPORTANT DISCLOSURES**



Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution								
Data current as of 30 September 2007	Buy	Hold	Sell					
Citi Investment Research Global Fundamental Coverage (3358)	50%	38%	12%					
% of companies in each rating category that are investment banking clients	53%	55%	42%					

#### **Guide to Fundamental Research Investment Ratings:**

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

6

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk rating. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underperform the relevant Sector index; or Sell/Underweight the bond is expected to underperform the relevant sector of the Citigroup indexes.

### **OTHER DISCLOSURES**

The subject company's share price set out on the front page of this Product is quoted as at 11 October 2007 01:11 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813). Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários. BACEN - Brazilian Central Bank. APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency

7

11 October 2007

(BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup or its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST